好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Self-Management for People with Epilepsy and a History of Negative Health Events (SMART): A Randomized Controlled Effectiveness Trial
Epilepsy/Clinical Neurophysiology (EEG)
P1 - Poster Session 1 (11:45 AM-12:45 PM)
9-007

This report describes a prospective 2-site, 6-month randomized controlled trial of an epilepsy self-management curriculum (SMART). We hypothesized SMART would be associated with reduced negative health events (NHEs) and improved quality of life (QOL), functioning, and physical and mental health.

Self-management programs are used for many chronic health problems but are underutilized in epilepsy. 

Adults with epilepsy with at least one NHE (seizure, emergency department visit, hospitalization, or self-harm attempt) were enrolled. The primary outcome was reductions in NHE/day from baseline to 6 months follow up. Secondary outcomes included depressive symptoms assessed with the Patient Health Questionnaire (PHQ-9), functioning by the 36-Item Short Form Survey (SF-36), QOL by the 31-item Quality of Life in Epilepsy (QOLIE-31), self-management competence by the Epilepsy Self-Management Scale (ESMS), stigma by the Epilepsy Stigma Scale (ESS), social support by the Multidimensional Scale of Perceived Social Support (MSPSS) and self-efficacy by the Epilepsy Self-Efficacy Scale (ESES).

The sample consisted of 160 participants with a mean age of 39.4 (SD 12.2) years, 66.9% (N=107) women, 82.5% (N=132) white and 31% (N=50) from rural regions.  Mean depression severity was in the mild/moderate range with a mean PHQ-9 of 10.5 (SD 7). The mean duration of epilepsy was 15.5 (SD 13.8) years and the mean seizure count in the 6 months prior to baseline was 20.6 (SD 41.0). While total NHE counts were similar between arms, in logistic regression models, SMART had 2-fold increased odds of having 10-30% improvement in NHE numbers compared to waitlist (p<0.05). SMART was associated with significantly improved PHQ-9 (p=.014), QOLIE-31 seizure worry (p=<.001) and social functioning (p=.021), ESES (p=.046), and ESMS (p<.001).

Participating in SMART increased the likelihood of having a clinically relevant improvement in NHE and improved depressive symptoms, epilepsy self-management competency, self-efficacy, and elements of QOL.

Authors/Disclosures
MARTHA SAJATOVIC, MD
PRESENTER
Dr. SAJATOVIC has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck, Janssen, Teva, Otsuka, Alkermes. The institution of Dr. SAJATOVIC has received research support from Neurelis, Intra-Cellular, Merck, Otsuka, Alkermes, International Society for Bipolar Disorders (ISBD), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), . Dr. SAJATOVIC has received publishing royalties from a publication relating to health care.
Gena R. Ghearing, MD (Mount Sinai) The institution of Dr. Ghearing has received research support from Center for Disease Control and Prevention.
Maegan Tyrrell, CCRP Ms. Tyrrell has nothing to disclose.
Jessica Black, BA Ms. Black has nothing to disclose.
Jacqueline Krehel-Montgomery, BA Mrs. Krehel-Montgomery has nothing to disclose.
Richard Barigye, Msc Mr. Barigye has nothing to disclose.
Joy Yala (Case Western Reserve University School of Medicine) No disclosure on file
Michael D. Privitera, MD, FAAN (Univ of Cincinnati/Dept of Neurology) Dr. Privitera has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SK life science. Dr. Privitera has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuroPace. Dr. Privitera has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for SK life science. Dr. Privitera has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Jazz. The institution of Dr. Privitera has received research support from Neurelis. The institution of Dr. Privitera has received research support from Biohaven. Dr. Privitera has received research support from Neurava.
Marvin A. Rossi, MD, PhD (Rush University Medical Center) Dr. Rossi has nothing to disclose.
Farren Briggs, PhD (University of Miami Miller School of Medicine) The institution of Prof. Briggs has received research support from NIH.